You are here
Third Positive Recommendation From Independent Safety Review Board Encourages the Continuation of Alzhemed Trial
Neurochem's ISRB for Alzhemed(TM) is made up of independent medical experts who monitor and evaluate the safety of patients taking part in the Alzhemed(TM) Phase III clinical trial in North America.
Alzhemed(TM) has entered into a multicenter, randomized, double-blind, placebo-controlled, three-armed, parallel-design Phase III clinical trial; 68 clinical centers have been enrolled in North America. A total of 1,052 patients have been randomized to receive study medication over a period of 18 months. The Company also launched its Phase III clinical trial in Europe in September 2005.
Source: Neurochem Inc. Alzhemed(TM) is an orally administered, small organic molecule that has been specifically designed to modify the course of AD through its anti-amyloid activity. As part of a "disease modifying" novel class of product candidates, Alzhemed(TM) is expected to act at two levels: by preventing and stopping the formation and the deposition of amyloid fibrils in the brain and by binding to soluble A(beta) protein to reduce the amyloid-induced toxicity on neuronal and brain inflammatory cells associated with amyloid build-up in AD.